Effectiveness and safety of daclatasvir plus asunaprevir for chronic HCV genotype 1 infection

Trial Profile

Effectiveness and safety of daclatasvir plus asunaprevir for chronic HCV genotype 1 infection

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Feb 2017 Status changed from recruiting to completed.
    • 07 Dec 2015 According to University Hospital Medical Information Network - Japan record, study type changed from observational to interventional open label study.Also, planned number of patients changed from 150 to 400.
    • 07 Dec 2015 Planned number of patients changed from 150 to 400, as reported by University Hospital Medical Information Network - Japan record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top